Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease
- 30 June 2002
- journal article
- review article
- Published by Elsevier BV in Clinical Immunology
- Vol. 103 (3), 231-242
- https://doi.org/10.1006/clim.2002.5191
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell CulturesBiochemical and Biophysical Research Communications, 1998
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Molecular Cloning of Human cDNA for Cathepsin K: Novel Cysteine Proteinase Predominantly Expressed in BoneBiochemical and Biophysical Research Communications, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin‐1βArthritis & Rheumatism, 1992
- Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface.The Journal of cell biology, 1991
- Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.The Journal of Experimental Medicine, 1985